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The human complement factor H-related protein-3 (FHR-3) is a soluble regulator of the 
complement system. Homozygous cfhr3/1 deletion is a genetic risk factor for the autoim-
mune form of atypical hemolytic-uremic syndrome (aHUS), while also found to be protec-
tive in age-related macular degeneration (AMD). The precise function of FHR-3 remains 
to be fully characterized. We generated four mouse monoclonal antibodies (mAbs) for 
FHR-3 (RETC) without cross-reactivity to the complement factor H (FH)-family. These 
antibodies detected FHR-3 from human serum with a mean concentration of 1 μg/mL. 
FHR-3 levels in patients were significantly increased in sera from systemic lupus ery-
thematosus, rheumatoid arthritis, and polymyalgia rheumatica but remained almost 
unchanged in samples from AMD or aHUS patients. Moreover, by immunostaining of an 
aged human donor retina, we discovered a local FHR-3 production by microglia/mac-
rophages. The mAb RETC-2 modulated FHR-3 binding to C3b but not the binding of 
FHR-3 to heparin. Interestingly, FHR-3 competed with FH for binding C3b and the mAb 
RETC-2 reduced the interaction of FHR-3 and C3b, resulting in increased FH binding. 
Abbreviations: aHUS, atypical hemolytic-uremic syndrome; AMD, age-related macular degeneration; BSA, bovine serum 
albumin; BSR, blood sedimentation rate; CDR, complementarity-determining regions; CNV, choroidal neovascularization; 
CRP, C-reactive protein; CTD, connective tissue diseases; CYC, cyclophosphamide; DAPI, 4′,6-diamidino-2-phenylindole; 
DMARDs, disease-modifying antirheumatic drugs; ELISA, enzyme-linked immunosorbent assay; Fab, variable antigen binding 
part of an immunoglobulin; Fc, constant part of an immunoglobulin; FH, complement factor H; FHR, FH-related protein; HRP, 
horseradish peroxidase; Ig, immunoglobulin; IgAN, IgA nephropathy; IVIG, intravenous immunoglobulins; mAb, monoclonal 
antibody; MNS, mouse normal serum; NHS, normal human serum; pAb, polyclonal antibody; PR, polymyalgia rheumatica; 
RA, rheumatoid arthritis; RETC, regensburg therapy complement; SCR, short consensus repeat domain; SLE, systemic lupus 
erythematosus; SPA, spondyloarthritis; SSc, systemic sclerosis; TMB, 3,3′,5,5′-tetramethylbenzidine.
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inTrODUcTiOn
The human complement factor H-related protein 3 (FHR-3) 
belongs to the complement factor H (FH)-family. This family, 
consisting of seven proteins [FH, FH-like protein 1, FH-related 
protein (FHR) 1–5], are secreted plasma proteins and important 
regulators of the complement system (1).
The five cfhr genes are located on chromosome 1q31.3, 
downstream of the cfh gene (2), coding for FH-family members, 
which share high sequence identities within their short consensus 
repeat (SCR) domains. FHR-3 is composed of five SCR domains, 
which display similarities with SCR6–8 (91–62%) and SCR19–20 
(64–37%) of FH (1, 3, 4). Indeed, unambiguous identification 
and modulation of FHR-3 is challenging considering their high 
protein sequence similarity. Reported normal systemic FHR-3 
concentrations ranged between 0.02 and 100 μg/mL (5–7). The 
molecular function of FHR-3 is only partly clarified and contro-
versially discussed in the literature (1, 8).
The deletion of the genes for cfhr1 and cfhr3 are a double-
edged sword as it was genetically associated with protection 
against age-related macular degeneration (AMD) (9–11) and IgA 
nephropathy (IgAN) (12), or was associated to be a genetic risk 
factor for atypical hemolytic-uremic syndrome (aHUS) (13, 14) 
as well as systemic lupus erythematosus (SLE) (15). FHR-3 was 
also found in middle ear fluid following alternative complement 
pathway activation due to infections and was associated with 
pro-inflammatory activity (16).
Diverse local functions of FHR-3 at different injury-associated 
altered surfaces were studied (17). All FHR proteins bind to C3b, 
the central protein of the complement C3- and C5-convertases. 
Three of the five FHR proteins (FHR-1, FHR-3, and FHR-5) com-
pete with FH for binding to C3b. Thereby, on the one hand, they 
promote alternative complement pathway activation (5, 18). On 
the other hand, FHR-3, FHR-4, and FHR-5 show a weak cofactor 
activity in degradation of C3b by factor I resulting in a reduced 
alternative pathway activity (1, 3).
According to the gene association studies mentioned before, 
therapeutic inhibition of FHR-3 could be beneficial in AMD or 
IgAN, while a drug-dependent increase of FHR-3 activity could be 
a potential strategy for treatment of aHUS and SLE. A published 
monoclonal antibody (mAb) against FHR-3 is highly specific, but 
its effect on the function of FHR-3 has not been evaluated (19). 
We hypothesize that specific anti-FHR-3 mAbs have the potential 
to clarify and to modulate the function of FHR-3.
Here, we describe novel-specific mAbs of different isotypes 
against human FHR-3. Using the highly specific mAb RETC-2 
for the evaluation of FHR-3 levels in different human serum 
samples revealed a significantly increased FHR-3 concentration 
in rheumatoid patient samples. Furthermore, we identified local 
production of FHR-3 by microglia/macrophages in an aged donor 
retina with RPE atrophy – the latter being a typical hallmark 
of dry AMD. Additionally, we demonstrate that FHR-3 mAb 
RETC-2 reduced binding of FHR-3 to C3b reinforcing the local 
binding of the FHR-3 competing complement inhibitor FH. Thus, 
FHR-3-targeting therapeutics may offer an innovative strategy for 
local immune therapies for AMD and other complement-related 
diseases.
MaTerials anD MeThODs
human Material, animals, and ethical 
statements
Collection of human blood and eye samples were approved by 
the local ethics committees (serum: University of Regensburg and 
Friedrich Schiller University Jena, Germany; eyes: University of 
Bern, Switzerland) and were obtained in accordance with the 
Declaration of Helsinki. Complement-depleted human sera were 
purchased from Complement Technology (Tyler, TX, USA). 
All human serum samples were stored at −80°C. Balb/c and 
C57/BL6 mice were obtained from Charles River Laboratories 
(Wilmington, MA, USA). Mice experiments were strictly per-
formed according to the guidelines of replacement, refinement, 
and reduction of animals in research (20) and approved by the 
committee on the ethics of animal experiments of the regional 
agency for animal health Regierung der Oberpfalz, Veterinärwesen 
(TVA 54-2532.4-05/13).
Proteins and antibodies
FHR-1, FHR-2, and FHR-5 purified proteins were obtained 
from Novoprotein (Summit, NJ, USA). Recombinant FHR-4A 
and FHR-4B were purified as previously described (6). FH and 
C3b were ordered from Complement Technology (Tyler, TX, 
USA). Bovine serum albumin (BSA) was purchased from SERVA 
Electrophoresis GmbH (Heidelberg, Germany). Heparin-biotin 
was obtained from Sigma-Aldrich (Munich, Germany).
The goat polyclonal antihuman FH antibody was obtained 
from Quidel (cat. A312, San Diego, CA, USA), the mouse mAb 
anti-FH was a kind gift of S. Berra (Università degli Studi di 
Milano, Milano, Italy) (21), and mouse mAb anti-FHR-3.1 and 
anti-FHR-3.4 were described previously (6). Rabbit anti-Iba1 
polyclonal antibody was ordered from Wako Chemicals (cat. 019-
19741, Neuss, Germany), and mouse anti-Glutamine Synthetase 
mAb, clone GS-6, was from Calbiochem/Merck Millipore (cat. 
MAB302, Darmstadt, Germany). StrepMAB-classic (cat. 2-1507-
001) and StrepMAB-classic conjugated to horseradish peroxidase 
Our results unveil a previously unknown systemic involvement of FHR-3 in rheumatoid 
diseases and a putative local role of FHR-3 mediated by microglia/macrophages in the 
damaged retina. We conclude that the local FHR-3/FH equilibrium in AMD is a potential 
therapeutic target, which can be modulated by our specific mAb RETC-2.
Keywords: Fhr-3/cFhr3, specific antibody, rheumatic disease, microglia/macrophage, Fh competition, immune 
therapy, retinal degeneration
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(HRP) (cat. 2-1509-001) were sourced from IBA (Goettingen, 
Germany). Immunofluorescence secondary antibodies: rabbit 
anti-goat Alexa Fluor 546-conjugate (cat. A21085), goat anti-
rabbit Cy3-conjugate (cat. A10520), and DAPI (4′,6-diamidino-
2-phenylindole, dihydrochloride) were purchased from Thermo 
Fisher Scientific (Braunschweig, Germany); goat anti-mouse 
CF488A-conjugate antibody (cat. 20018-1) was ordered from 
Biotium (Hayward, CA, USA). Rabbit anti-goat IgG-HRP (cat. 
305-035-003) and goat anti-mouse IgG-constant part of immu-
noglobulin (Fc)γ-HRP (cat. 115-035-164) were purchased from 
Jackson ImmunoResearch (West Grove, PA, USA).
The immunogenic peptide within SCR5 (Charité Universi-
tätsmedizin Berlin, Institute of Biochemistry, Laboratory Pro-
teolytic Systems, Berlin, Germany) was conjugated either to BSA 
for mouse immunization or to keyhole limpet hemocyanin for 
ELISA screening of positives clones.
expression of recombinant Fhr-3
The construct pCAG-cfhr3 (22), containing the cfhr3 sequence 
with a C-terminal Strep-tag II, was transiently inserted into 
human embryonic kidney cells 293 (HEK293, Life Technologies, 
Carlsbad, CA, USA) with TransIT-LT1 Transfection Reagent 
(Mirus, Madison, WI, USA), according to the manufacturer’s 
protocol. FHR-3 with Strep-tag II was purified from HEK293 
supernatant and cell lysate using Strep-Tactin Sepharose columns 
(IBA, Goettingen, Germany) (23). After gradient elution of 
FHR-3 using Strep-Tactin Sepharose columns (IBA, Goettingen, 
Germany), the recombinant protein was concentrated by vacuum 
centrifugation. Protein purity was detected with Coomassie 
staining and Western blot.
generation of mabs
Mouse mAbs against human FHR-3 were generated by hybridoma 
technology (24). Briefly, mice were subcutaneously immunized 
with 50 μg peptide-BSA in Freund’s adjuvants (Sigma-Aldrich, 
Munich, Germany). Spleen cells were isolated, fused, and culti-
vated as described previously (25). Hybridoma supernatants were 
tested for specific FHR-3-binding by ELISA. Protein-G affinity 
purified antibodies from hybridoma clones (HiTrap Protein 
G HP affinity column, GE Healthcare Life Science, Piscataway, 
NJ, USA) were named as follows (antibody:hybridoma): RETC 
(REgensburg Therapy Complement)-2:269-5, RETC-3:353-1, 
RETC-5:552-3, and RETC-7:773-17.
Determination of antibody Variable 
regions
RNA of hybridoma cell lines was isolated using RNeasy Mini 
Kit (Qiagen, Hamburg, Germany) and subsequent synthesis of 
cDNA using the Quantitect reverse Transcription Kit (Qiagen, 
Hamburg, Germany). PCR for amplification of IgG variable 
regions (heavy and light chain) was performed using the mouse 
IgG Library Primer set (Progen, Heidelberg, Germany), according 
to the manufacturer’s protocol and DNA-fragments were ligated 
into pGEM-T Easy plasmid (Promega, Mannheim, Germany) 
for E.  coli XL-1 Blue competent cells (Agilent Technologies, 
Boeblingen, Germany) transformation. Following plasmid 
isolation (Plasmid Midi Kit, Qiagen, Hamburg, Germany), 
DNA-sequencing was performed by GeneArt (Thermo Fisher 
Scientific, Braunschweig, Germany) with pGEM-T specific 
primer M13 (Promega, Mannheim, Germany).
indirect elisa for antibody analyses
PolySorp microtiter plates (Nalgene Nunc, Penfield, NY, USA) 
were coated with antigen (5 μg/mL, PBS, overnight, 4°C). Each 
incubation step was finalized with three consecutive washing 
steps (PBS-T, PBS, 0.1% Tween 20). Blocking was performed 
with 2% skim milk in PBS/T (1 h). After incubation with anti-
FHR-3 mAbs (2% skim milk in PBS-T, 1 h), detection followed by 
goat anti-mouse IgG-Fcγ-HRP (1:2500, 2% skim milk in PBS-T, 
30  min) and 3,3′,5,5′-tetramethylbenzidine (TMB, Seramun 
Diagnostica GmbH, Heidesee/Wolzig, Germany). Optical den-
sity (absorption) was determined at 450 nm.
immunoprecipitation of Fhr-3 from 
human serum
Five milligrams of tosylactivated dynabeads (Life Technologies, 
Carlsbad, CA, USA) were either conjugated to 100  μg mAb 
RETC-2, mAb RETC-3, or the respective IgG isotype controls 
according to the manufacturer’s protocol. Pooled normal human 
serum (NHS, 1.5 mL) was incubated with mAb-coupled dyna-
beads (50 μL, 1  h). After washing, proteins were eluted using 
non-reducing Laemmli sample buffer (10 min, 95°C) (26).
gel and non-gel lc-Ms/Ms analyses
Samples were separated by SDS-PAGE and stained with 
Coomassie. Afterward, all visible bands were excised and sub-
jected to in-gel-digestion as published previously (27). Resulting 
peptides were used for nano-LC-MS/MS analysis on a TripleTOF 
5600+ mass spectrometer (Sciex, Darmstadt, Germany) as 
published previously (24). Database searches were accomplished 
using the ProteinPilot 4.5 software using the Uniprot-database 
(version 05/2014).
Samples for non-gel LC-MS/MS were diluted in 50  mM 
ammoniumcarbonate, then reduced with 100 mM dithiothreitol 
for 30 min at 60°C, and alkylated with 300 mM iodoacetamide at 
room temperature. Trypsin-mediated proteolysis was performed 
using a modified Filter-Aided Sample Preparation protocol 
as published previously (28). Resulting peptides were used 
for analysis on a LTQ-Orbitrap XL (Thermo Fisher Scientific, 
Braunschweig, Germany) connected with an Ultimate 3000 
nano-HPLC system (Thermo Fisher Scientific, Braunschweig, 
Germany) as described previously (29). Peptides were identified 
and quantified using the Progenesis QI software (Non-linear, 
Waters) and the Mascot search algorithm with the Ensembl 
Human public database (29, 30).
Protein gel and Western Blot analyses
Immunoprecipitated samples, purified recombinant human 
proteins (2 μg) or NHS (100 μg), were separated, either on a non-
reducing 10% SDS-PAGE or on a reducing 12% SDS-PAGE with 
subsequent short colloidal Coomassie staining (31), or proteins 
were transferred onto polyvinylidene difluoride membranes. 
Membranes were blocked (3% BSA/PBS-T, 1 h) and subsequently 
incubated with biotinylated mAb RETC-2 (5–10  μg/mL, 3% 
4Schäfer et al. Specific Antibodies for FHR-3
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BSA/PBS-T, 4°C, overnight). Membranes were treated with 
streptavidin-HRP (1:2500 in 3% BSA/PBS-T, 30 min) and devel-
oped with Lumi-Light blotting substrate (Roche Diagnostics 
GmbH, Mannheim, Germany).
sandwich-elisa for Determination of 
Fhr-3 concentrations in human serum
MaxiSorp microtiter plates (Nalgene Nunc, Penfield, NY, USA) 
were coated with capture antibody mAb RETC-2 (10 μg/mL in 
PBS, overnight, 4°C) and blocked with 2% skim milk in PBS-T 
(1 h). Human serum samples (1:20, 1:40) and recombinant FHR-3 
(1.4–1000 ng/μL), diluted in 2% skim milk in PBS-T, were incu-
bated (1  h) for quantification. Followed by an incubation with 
biotin-labeled detection antibody mAb anti-FHR-3.4 (0.3 μg/mL) 
in 2% skim milk in PBS-T (1 h), detection of sandwich ELISA was 
performed with streptavidin-HRP (1:5000, 2% skim milk in PBS-
T, 30 min) and TMB. Optical density was determined at 450 nm.
genetic analysis
Genomic DNA was isolated from whole blood (P1, P2, N1, 
N2) (32). Amplification of the cfhr3 gene and sequence analy-
sis were performed using specific primers (R3) as described 
previously (14).
immunohistochemistry
Enucleated donor eyes fixed in 4% paraformaldehyde (48 h) were 
rinsed in PBS/0.05% azide, and the anterior segment was removed. 
The eyecups were cryo-protected in a 10–30% sucrose gradient 
(3 days) and embedded in frozen section medium Neg-50 (Thermo 
Fisher Scientific, Braunschweig, Germany). Immunofluorescence 
was performed on 25-μm thick sections. The slides were treated 
with blocking solution (PBS containing 3% DMSO, 0.3% Triton 
X-100, and 5% normal donkey serum) to reduce non-specific 
background (1 h). Primary antibodies [RETC-2, 60 μg/mL; rabbit 
anti-Iba1 polyclonal antibody, 1 μg/mL; goat anti-FH polyclonal 
antibody, 60 μg/mL; mouse anti-glutamine synthetase monoclo-
nal antibody (mAb), 2 μg/mL] were incubated in blocking solu-
tion (overnight). Antibody binding was detected with secondary 
antibodies (goat anti-mouse CF488A-conjugate antibody, 1:1000; 
goat anti-rabbit Cy3-conjugate antibody, 1:500; rabbit anti-goat 
Alexa Fluor 546-conjugate antibody, 1:1000). Cell nuclei were 
stained with DAPI (1:1000). Images were taken with a custom-
made VisiScope CSU-X1 Confocal System (Visitron Systems, 
Puchheim, Germany) equipped with a high-resolution sCMOS 
camera (PCO AG, Kehlheim, Germany).
real Time qrT-Pcr
Primary RPE/choroid and retina were dissected from an unfixed 
human eye. Retinal cell populations were separated using mag-
netic-activated cell sorting (MACS) as described in Grosche et al. 
(33). Human RPE for cultivation was isolated from healthy donor 
eyes (age 86 and 65  years) and treated as previously described 
(34). ARPE19 cells were purchased from ATCC (LGC Standard 
GmbH, Wesel, Germany) and cultivated as reported earlier (35). 
Human liver cDNA was kindly provided by V. M. Milenkovic 
(Department of Psychiatry and Psychotherapy, University 
Regensburg). mRNA of the cells was isolated (NucleoSpin RNA/
Protein Kit, Macherey-Nagel, Düren, Germany), and cDNA 
was synthesized (Quantitect Reverse Transcription Kit, Qiagen, 
Hilden, Germany). qRT-PCR was performed using Quantitect 
primer sets (chfr3: QT00001631, cfh: QT00001624, gapdh: 
QT00079247) and Rotor Gene Sybr green PCR Kit (Qiagen, 
Hilden, Germany). Taqman PCR was performed using Brilliant 
III UF MM QPCR/Low ROX master mix (Agilent Technologies, 
Waldbronn, Germany) and the following cfhr3-specific primer 
(cfhr3-forward: gtttgcaaaatggatggtca; cfhr3-reverse: ggaggtggtat-
caccattgc) and the FAM-labeled probe #25 (Roche Diagnostics, 
Mannheim, Germany).
elisa for c3b interaction
PolySorp microtiter plates (Nalgene Nunc, Penfield, NY, USA) 
were coated with C3b (10 μg/mL, PBS, overnight, 4°C). Blocking 
was performed with Casein Diluent Blocker (Senova GmbH, 
Weimar, Germany) (1 h). FHR-3 [10 μg/mL (200 nM)] and anti-
FHR-3 mAb RETC-2 [100 μg/mL (666 nM)] were preincubated 
in PBS (1 h). Incubation of FHR-3, FH [2.6 μg/mL (16 nM)], and 
FHR-3 with anti-FHR-3 mAb RETC-2 on C3b plates (15 min) 
was performed. For the standard curves antigen serial dilutions 
(FHR3 0.7–1500 nM, FH 0.2–6451.6 nM, PBS) were incubated 
(1  h). Binding was detected either with mouse anti-FH mAb 
(2.5 μg/mL, PBS, 1  h) and anti-mouse IgG-HRP (1:5000 PBS, 
30 min) or StrepMAB-HRP (1:40000, 30 min, PBS). The signal 
was developed with TMB, and the optical density (absorption) 
was determined at 450 nm.
sandwich elisa for heparin interaction
MaxiSorp microtiter plates (Nalgene Nunc, Penfield, NY, USA) 
were coated with StrepMAB-classic (10  μg/mL in PBS, 4°C, 
overnight). After blocking (5% BSA/PBS-T, 1  h), recombinant 
human FHR-3 [250 μg/mL (5 μM)] with Strep-tag in PBS was 
incubated (1 h). Prior to heparin-biotin addition (100 μg/mL, 5% 
BSA/PBS-T, 1 h), anti-FHR-3 mAb or specific isotype control was 
incubated (8 mg/mL (53 μM), PBS, 1 h). Detection was followed 
by streptavidin-HRP (1:5000, PBS, 30 min) and TMB. The signal 
was measured at 450 nm.
software and statistical analyses
Immunogenic and unique peptides of SCR5 were determined by 
AbDesigner (36). Sequence analyses of mAb RETC-2 and mAb 
RETC-3 variable regions were performed with VBASE2 (37) 
and Rosetta online (38) server. The visualization of antibody 
structures and complementarity-determining regions (CDR) was 
realized with Chimera (39). Data were statistically analyzed using 
GraphPad Prism 5 (GraphPad Software, San Diego, CA, USA).
resUlTs
novel Mouse mabs specifically interact 
with human Fhr-3
We generated four different mouse hybridoma cell lines against 
native human FHR-3 using a peptide immunization strategy. 
The isolated and purified four mAbs RETC-2, RETC-3, RETC-5, 
TaBle 1 | summary of anti-Fhr-3 mab and isotype controls.
reTc-2 reTc-5 igg2b control reTc-3 reTc-7 igg1 control
species Mouse Mouse Mouse Mouse Mouse Mouse
antigen FHR-3a FHR-3a Unknown FHR-3a FHR-3a BSA
isotype IgG2b, κ IgG2b, κ IgG2b, κ IgG1, κ IgG1, κ IgG1, κ
elisa
FHR-3 + + − + + −
FHR-1 − − − − − −
FHR-2 − − − − − −
FHR-4A − n. d. − n. d. n. d. n. d.
FHR-4B − n. d. − n. d. n. d. n. d.
FHR-5 − − − − − −
FH − − − − − −
BSA − − − − − +
NHS + + − + n. d. −
Western blot
FHR-3 + + − + + −
FHR-4A − n. d. n. d. n. d. n. d. n. d.
FHR-4B − n. d. n. d. n. d. n. d. n. d.
FH − − − − − −
BSA − − − − − +
NHS + + − + n. d. −
Fhr-3-specific iP + n. d. − + n. d. −
Mab-influence in protein interaction
C3b-FHR-3 ↓ n. d. n. d. n. d. n. d. n. d.
C3b-FH/FHR-3-competition ↑ n. d. n. d. n. d. n. d. n. d.
Heparin-FHR-3 − n. d. n. d. n. d. n. d. n. d.
aSCR5 domain.
n. d., not determined.
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and RETC-7 were specific for the C-terminal, fifth SCR (SCR5) 
domain of FHR-3.
These antibodies were of different mouse isotypes. MAb 
RETC-3 and mAb RETC-7 were mouse IgG1 antibodies. MAb 
RETC-2 and mAb RETC-5 were mouse IgG2b isotypes (Table 1). 
κ-light chains complemented the FHR-3 binding structures of 
the variable heavy chain regions. Sequence analysis and in silico 
simulations revealed the specific, variable paratope structure 
(Fab), including the CDRs of mAb RETC-2 and mAb RETC-3 
(Figure S1 in Supplementary Material).
Our analysis of the specificity of all four anti-FHR-3 mAbs dis-
closed significant detection of recombinant FHR-3 in ELISA and 
Western blots (Figures 1A,B; Table 1), neither FHs, related FHR-
1, FHR-2, FHR-4A, FHR-4B, nor FHR-5 proteins, were bounded 
(Figures 1A,B; Table 1). All antibodies interacted with the same 
11-amino acid long epitope in SCR5, albeit with different bind-
ing strengths (Figure 1C). The mouse IgG2b mAbs revealed the 
highest avidity to FHR-3, including RETC-2 (EC50 = 256 ng/mL) 
and RETC-5 (EC50 = 445 ng/mL), which differed by a factor of 
1.7 (Figure 1C). The IgG1 mAbs RETC-3 (EC50 = 1617 ng/mL) 
and RETC-7 (EC50 = 19849 ng/mL) showed a 6–77 times lower 
binding strength to recombinant FHR-3 than the IgG2b mAbs 
(Figure  1C). Primarily, the antibody-target epitope interaction 
of mAb RETC-2 was characterized in-depth as this mAb showed 
the highest avidity against immobilized, recombinant FHR-3 
(Figure 1C).
We confirmed the specificity of anti-FHR-3 mAbs for FHR-3 
produced naturally in the body by analyzing human blood 
samples in Western blots. FHR-3 was detected as a monomer 
in different FHR-3-glycoforms (between 35–65 kDa) in human 
serum without enrichment and under reducing conditions using 
anti-FHR-3-specific mAb RETC-2 (Figure 2A, arrows; Table 1). 
The glycoforms correspond to the previously described four 
glycosylation sites of FHR-3 (13, 40). MAb RETC-2 showed a 
detection ratio of 1:8:4:0.1 corresponding to the putative FHR-3 
glycoforms at 65, 50, and 40 kDa, as well as a hardly detectable 
non-glycosylated form at 35 kDa (Figure 2A, arrows). Detection 
of FHR-3 using mAb RETC-2 from human serum under non-
reducing conditions resulted in additional protein signals at 
approximately 90–100 kDa (Figure 2B).
Mouse Ig interacts with their variable Fab-part with the cor-
responding target epitope (Figure 1), and their constant Fc-part 
is recognized by Fc-receptors or complement components (41, 
42). We used a combination of gel-based (Figure 2B) and non-gel 
FigUre 2 | Mab reTc-2 detected native Fhr-3 in complex with other complement proteins from human serum. (a) MAb RETC-2 detected four protein 
bands for FHR-3-glycoforms between 35 and 65 kDa (arrows) from reduced normal human serum (NHS) in Western blot. (B) More than 30 different proteins were 
immunoprecipitated from non-reduced NHS using RETC-2 and isotype control (not shown). Labeled fractions after Coomassie staining were identified by mass 
spectrometry analyses and contained FHR-3. Unlabeled protein bands contained other serum proteins (e.g., serum albumin, apolipoproteins, Igs). (c) RETC-2 
specifically precipitated FHR-3 (green star) in comparison to an isotype control mAb. Additional peptide fragments, characterized with non-gel LC-MS/MS, were 
complement proteins.
FigUre 1 | Mouse mabs were specific for recombinant human Fhr-3. (a) MAb RETC-2 reacted exclusively with FHR-3 but not with other proteins of the 
FH-family in ELISA. MAb RETC-3, RETC-5, and RETC-7 showed the same detection pattern (data not shown, see Table 1). (B) MAb RETC-2 revealed a specific 
detection of FHR-3 compared to the highly identical FHR-4A and FHR-4B (94% identity to FHR-3) in Western blot. Detection of recombinant proteins was 
performed either with mAb RETC-2 or with mAb anti-FHR-3.1. (c) MAbs RETC-2 and mAb RETC-5 (IgG2b mAbs) showed the highest binding signals for human, 
recombinant FHR-3 immobilized on microtiter plates.
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LC-MS/MS (Figure  2C) protein identifications to dissect the 
interactions into Fab-part (anti-FHR-3 specific) and Fc-part 
(general mouse Ig isotype specific) mechanisms. Therefore, we 
compared the precipitated protein patterns from native human 
serum using either anti-FHR-3 mAb RETC-2 or the corre-
sponding isotype Ig (Figures 2B,C; Table S1 in Supplementary 
Material). Fab-specific FHR-3 counts were exclusively identified 
in immunoprecipitations using the novel anti-FHR-3 mAb at 
different protein sizes (Figures 2B,C), but not with the isotype 
controls (Figure  2C; Table S1 in Supplementary Material). 
In contrast, FH and FHR-5 bound to all mouse IgG2b whereas 
FHR-1, FHR-2, or FHR-4 did not interact with the IgGs (Table S1 
in supplementary material). Given the fact that no other 
FH-family members were consistently detected in combination 
with FHR-3, the data suggested that FHR-3 circulates in vivo as a 
monomer or as a homo-multimer.
The constant, non-specific Fc-antibody parts of both the 
anti-FHR-3 mAb and the isotype control mAb precipitated 
additional serum proteins (Table S1 in supplementary material). 
Separation of mAb RETC-2 precipitated proteins by SDS-PAGE 
with subsequent Coomassie staining revealed protein bands with 
20 different mobilities (Figure  2B) and 10 bands with isotype 
control (data not shown). On average, 30 different proteins were 
identified as Fc- and/or immunoprecipitation-beads associated 
interaction partners for both the FHR-3 specific and the cor-
responding isotype control antibodies. These proteins included 
abundant proteins, such as keratin, apolipoproteins, Igs, and 
serum albumin. Our analysis focused on complement-associated 
proteins. More than 20 human complement proteins of all 
three complement activation pathways bound to the murine 
Fc-antibody parts IgG1 or IgG2b, irrespective of the antibodies 
specificity (Fab-part) (Figure  2C; Table S1 in Supplementary 
FigUre 3 | Fhr-3 quantification resulted in significantly increased Fhr-3 serum concentrations for sle, ra, and Pr patients. (a) Quantified FHR-3 
serum levels, using a sandwich immunoassay showed a reproducible, specific detection pattern in concentration range between 0.5 and 1.7 μg/mL. Technical 
replicates from each sample are shown as calculated FHR-3 concentrations in μg/mL (standard curve not shown). (B) Immunoblots correlated with FHR-3 detection 
in the immunoassay and showed two bands between 50 and 55 kDa for specific FHR-3 immunoprecipitation from reduced serum samples. (c) Cfhr3 genotyping 
was consistent with FHR-3 immunodetection. (D) Systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and polymyalgia rheumatica (PR) patients showed 
an increased FHR-3 concentration compared with healthy controls (Table S2 in Supplementary Material) in the immunoassay (aHUS, atypical hemolytic-uremic 
syndrome; CNV, choroidal neovascularization; SSc, systemic sclerosis; SPA, spondyloarthritis; CTD, connective tissue diseases). Means of two independent 
quantifications are shown. ***p < 0.001, **p < 0.01, *p < 0.1 (two-tailed, unpaired t-test).
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Material). The human complement proteins C3 and C5 were 
detected with the highest spectral counts as binding partners for 
all mouse Fc-parts (Figure 2C). MAbs RETC-2, RETC-3 as well 
as the corresponding isotype controls precipitated also proteins of 
the terminal pathway (C6–C9) and important soluble regulators 
(clusterin, vitronectin, properdin) (Table S1 in Supplementary 
Material). In addition, characteristic components of the classical 
pathway (C1, C2, C4), the lectin pathway (MASP1, ficolin-2), 
and the alternative pathway (CFB) were associated with mouse 
IgG2b but not with mouse IgG1 Fc-parts antibodies (Table S1 in 
Supplementary Material).
In conclusion, these results showed that the specific FHR-3-
antibodies detected FHR-3 from human serum. However, we 
confirmed a general interaction of human complement proteins 
with the mouse Fc-antibody part. We concluded that mAb 
RETC-2 will need to be humanized in the future for further 
functional interaction studies involving this mAb and human 
serum containing all complement proteins.
Quantified Fhr-3 levels Varied in 
rheumatic Diseases and sle
An immunoassay for FHR-3 quantification from human samples 
was established, using mAb RETC-2 antibody as capture antibody 
and biotin-labeled anti-FHR-3.4 mAb (which reacts with FH and 
FHR-3) as detection antibody (6) (Figures 3A,D).
We performed chromosomal DNA analysis of leukocytes 
from healthy blood donors to determine positive and negative 
controls for the immunoassays. The positive samples (P1, P2) 
resulted in one specific 1.5  kb-fragment for the N-terminal 
cfhr3-gene region (SCR1/2), and negative samples (N1, N2) were 
homozygous for the cfhr3 deletion (Figure  3C). FHR-3 serum 
levels from healthy positive (P1, P2) and negative (N1–N3) 
controls were consistent with the respective genotype and were 
detected without any false-negative or false-positive signals in the 
immunoassay (Figures 3A,C). The ELISA and genotyping results 
(Figures 3A,C) correlated with the immunoblot detection, show-
ing protein bands at 50–55 kDa for FHR-3 positive serum samples 
and no signals for the FHR-3-deficient sera (Figure 3B).
Using this specific immunoassay, we aimed to determine 
FHR-3 levels in different standardized serum samples, using 
complement-deficient sera exemplarily (Figure  3A). Tested 
serum samples varied in their FHR-3 levels between 0.63 μg/mL 
for C3-depleted (C3dpl) and 1.69 μg/mL for C5dpl sera (Figure 3A). 
FHR-3 was not detected in FHdpl, IgGdpl, or normal mouse serum 
(Figures 3A,B). This is explained by heparin-based immunode-
pletion of FH from the serum that also removed heparin-affine 
FHR-3.
Repetitive FHR-3 quantification using positive control and 
complement-depleted sera revealed an interassay variation of the 
sandwich ELISA of 12–23% (Figure 3A).
We then investigated whether FHR-3 levels were systemically 
changed in complement-associated diseases (Figures 3D and 4; 
Table S2 in Supplementary Material). Serum samples from 
21 healthy, young (mean age 26) volunteers showed a FHR-3 
concentration of 0.41–2.49  μg/mL with a mean concentration 
of 1.06 +  0.53 μg/mL (Figure  3D; Table S2 in Supplementary 
Material), whereas the patient samples showed a FHR-3 con-
centration range of 0.31–12.29  μg/mL. On average, FHR-3 
FigUre 4 | Fhr-3 serum levels in sle patients correlated with lupus nephritis diagnose, steroid treatment, and blood sedimentation rate. FHR-3 
amounts in sera of SLE patients were determined in a FHR-3-specific immunoassay. We detected a significance difference in FHR-3 concentrations in patients (a) 
with acute lupus nephritis, (B) patients treated with steroids versus non-steroid treatment, and (c) patients with elevated blood sedimentation rates (BSR). However, 
(D) age, (e) sex, (F) medication, and (g) C-reactive protein (CRP) levels did not influence the systemic FHR-3 values in SLE patients in a biologically relevant 
manner. ***p < 0.001, **p < 0.001, *p < 0.1 (two-tailed, unpaired t-test).
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concentrations of patients with aHUS (mean 1.6 μg/mL), cho-
roidal neovascularization (CNV, mean 1.83  μg/mL), systemic 
sclerosis (SSc, mean 1.92 μg/mL), and connective tissue diseases 
(CTD, mean 1.76 μg/mL) were slightly increased (Figure  3D; 
Table S2 in Supplementary Material). However, serum samples 
from non-steroid-treated SLE, rheumatoid arthritis (RA), and 
polymyalgia rheumatica (PR) patients were associated with 
potentially biological relevant, significantly increased FHR-3 
serum levels (Figures  3D and 4; Table S2 in Supplementary 
Material). In our small cohort, the FHR-3  concentrations 
were threefold to fourfold higher in non- steroid-treated SLE 
(mean 4.14  μg/mL), RA (mean 3.12  μg/mL), and PR (mean 
3.37 μg/mL) patients in comparison to controls (Figures 3D and 
4B; Table S2 in Supplementary Material). Steroid treatment of 
SLE patients decreased the FHR-3 amounts in serum by 48% 
(Figure 4B). A correlation of FHR-3 levels and clinical parameters 
revealed a putative relation of FHR-3 levels and lupus nephritis 
diagnose or blood sedimentation rate (BSR) in SLE patients, 
respectively (Figures 4A,C). Increased C-reactive protein (CRP) 
levels in RA patients corresponded to higher FHR-3 concentra-
tions (Table S3 in Supplementary Material). FHR-3-deficient 
serum samples were mainly found in aHUS (38%), non-steroid 
treated SLE (17%), and in control (14%) cohorts (Table S2 in 
Supplementary Material). FHR-3 protein analyses in the aHUS 
group were confirmed by genetic analysis of all samples using 
multiplex ligation-dependent probe amplification (data not 
shown).
In summary, these experiments showed that FHR-3 levels 
in serum were altered in complement-associated inflammatory 
diseases. This suggested that systemic FHR-3 concentrations 
were associated with complement activity and inflammation.
Fhr-3 is localized in Microglia/
Macrophages and Fh in Müller cells  
in the retina
Previous studies revealed that FHR-3 deficiency is protective of 
AMD but a risk factor for the development of aHUS (9, 10, 13). 
We detected no critical differences in systemic FHR-3 protein 
concentrations of healthy donors compared with AMD or aHUS 
patients (Figure 3D). Therefore, a local effect of FHR-3 could be 
of relevance. We stained FHR-3 in a retina from a 92-year-old 
donor (Figure 5), which showed an increased number of invad-
ing macrophages (or activated microglia cells; Figures 5A,E) in 
comparison to a retina from a 64-year-old donor (Figures 5D,F). 
Surprisingly, we identified FHR-3 in activated microglia/mac-
rophages in the central retina of the 92-year-old donor using 
mAb RETC-2 (Figure  5A, arrows; Figures  5B,C, magnified). 
FHR-3 was not detected in resting microglia/macrophage in 
the periphery of the younger retina (Figure  5D). Fluorescent 
signals in the RPE (Figures 5A,D,F) were identified as unspe-
cific autofluorescence (Figure S2 in Supplementary Material). 
Interestingly, there is a patchy lag of autofluorescent RPE in 
the 92-year-old donor retina, indicative of local RPE atrophy. 
Invading macrophages and/or activated microglia were most 
prevalent in these tissue areas (Figures 5A,E). In contrast, the 
RPE appears to be largely intact in the 64-year-old control 
(Figures 5D,F).
FigUre 5 | Fhr-3 is localized in human retinal microglia/macrophage cells. FHR-3 (green) (a,D) was localized in microglia/macrophages (red) (a,D,e) in the 
central retina of the 92-year-old donor (arrows) (a), but not in microglia/macrophages of a 64-year-old donor retina (D). The marked area of (a) showing a microglia 
cell with an enlarged soma area, indicating microglia activation, is depicted in (B,c). Note the partial (a) and complete (e) absence of autofluorescent RPE in the 
sections from the 92-year-old donor. Stars in (a,e) indicate invading macrophages and/or leaving activated microglia cells. (e,F) show an isotype control for 
anti-FHR-3, co-stained with anti-Iba1, and demonstrated the differences of microglia/macrophage distribution in (e) the retina of the aged and (F) the younger 
donor. Retinal layers from the top to the bottom: GCL, ganglion cell layer; IPL, inner plexiform layer; INL, inner nuclear layer; OPL, outer plexiform layer; ONL, outer 
nuclear layer; PRS, photoreceptor segments; RPE, retinal pigment epithelium; BM, Bruch’s membrane; Ch, choroid. Scale bars, 40 μm.
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In order to confirm the local retinal FHR-3 production, mRNA 
expression analysis from eye tissue was performed. We isolated 
mRNA from different RPE cells (primary human RPE cells, culti-
vated human RPE cells, and ARPE19 cells), as well as human liver 
cells as control, and tested cfhr3 together with cfh expression using 
qRT-PCR (Figure S3 in Supplementary Material). Cfhr3 mRNA 
was only detected in liver cells but not in RPE-cells. However, cfh 
specific mRNA was determined in RPE and liver cells (Figure S3 
in Supplementary Material). Thus, different retinal cell types were 
separated from a human retina, and cfhr3 expression levels were 
compared to cfhr3-mRNA in ARPE19 cells using Taqman PCR 
(Figure S3 in Supplementary Material). Cfhr3 expression levels 
were 2- to 140-fold higher in microglia/macrophages isolated 
from human retina compared to other retinal cell types (Figure 
S3 in Supplementary Material).
Factor H-related protein-3 is highly identical to FH and inter-
acts with FH-binding partners. This suggested a similar binding 
pattern of FHR-3 and FH. Upon FH-staining of a human retina, 
Müller cells and photoreceptor cell segments were identified 
as FH-expressing cells (Figure  6). FH did not colocalize with 
FHR-3 in microglia/macrophages. The FH expression pattern in 
Müller cells appeared to be different in two investigated donor 
retinae. In the 92-year donor retina, the outer stem processes 
of Müller cells (Figures 6A–C), Müller cells enwrapping photo-
receptor somata or the photoreceptor somata itself, and Müller 
cell microvilli reaching into the layer of photoreceptor segments 
were FH-positive (Figures  6D,E). In contrast, in the 64-year-
old donor retina, FH labeling was more prominent in the inner 
stem processes (including perisynaptic side branches) of Müller 
glia spanning the inner plexiform layer (Figures  6D–F). This 
finding might be explained by the different degree of tissue 
damage as the disarranged retinal layers and activated micro-
glia/macrophages in the 92-year-old retina were indicative of a 
more pronounced tissue inflammation with concomitant RPE 
loss and neurodegeneration compared to the 64-year-old donor 
(Figures 6A,D,F).
In summary, these stainings of the human retina and expres-
sion analyses demonstrated that FHR-3 expression might be 
locally regulated and that it is likely to depend on the activation 
level of microglia/macrophages. Our novel anti-FHR-3 mAb 
RETC-2 revealed that FH and FHR-3 were expressed in retinal 
cell types with entirely different functions.
anti-Fhr-3 mab reTc-2 reduced 
Molecular interaction of Fhr-3 with  
c3b but not with heparin
Having shown that FHR-3 is expressed by microglia/macrophages 
in the retina (Figure 5), we asked whether our novel anti-FHR-3 
mAb RETC-2, directed against the SCR5 domain, interferes with 
the local binding characteristics of FHR-3. Therefore, we used 
competitive immunoassays to analyze the effect of mAb RETC-2 
on FHR-3 interactions.
Factor H-related protein-3 binds in vivo to C3b on cell surfaces 
mainly via a simultaneous interaction with glycosaminoglycan 
chains. C3b interacted in  vitro (without glycosaminoglycan 
chains) with recombinant FHR-3 and native FH (Figure  7A). 
The FHR-3–C3b interaction was not influenced by the addition 
of FH (Figure 7C). However, when anti-FHR-3 mAb RETC-2 was 
added to FHR-3 and C3b, the FHR-3-C3b binding was reduced 
by 32% (Figure  7C). This indicated either that in addition to 
SCR5 further domains are involved in the interaction of FHR-3 
FigUre 6 | Fh is localized in human Müller cells and photoreceptor cell segments. FH (orange a,D,F) colocalized with different cellular sub-compartments 
of retinal Müller glia (green a,D,F). In the 92-year-old human retina, FH was stained in the outer stem processes of Müller cells, which is shown in the marked area 
of (a) and depicted in (B,c). FH colocalized in the subretinal space of the 92-year old retina either with photoreceptor somata or with Müller cell processes 
enwrapping photoreceptor somata (D,e). The marked area of (D) is shown in (e). Stars in (a,D) indicate undefined subretinal debris. In the 64-year-old retina, FH 
was primarily present in the inner stem/perisynaptic processes of Müller cells and in Müller cell end feet (F–h). The magnified, marked area of (F) is shown in (g,h). 
Retinal layers from the top to the bottom: GCL, ganglion cell layer; IPL, inner plexiform layer; INL, inner nuclear layer; OPL, outer plexiform layer; ONL, outer nuclear 
layer; PRS, photoreceptor segments; RPE, retinal pigment epithelium; BM, Bruch’s membrane; Ch, choroid. GS, anti-glutamine synthetase mAb as Müller cell 
marker. Scale bars, 40 μm.
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with C3b or that the binding strength of mAb RETC-2 was not 
sufficient to replace FHR-3 completely.
In accordance with previous studies, we observed a competi-
tive effect of FHR-3 and FH for C3b binding (5) (Figure 7B). A 
molecular ratio above 12 FHR-3 to 1 FH molecule significantly 
reduced the binding of FH to C3b (Figure 7B). MAb RETC-2 
binding to FHR-3 ameliorated the FHR-3 interference with FH 
for C3b binding by 29% and resulted in an increased FH concen-
tration bound to C3b (Figure 7D). We found stronger RETC-2 
effects for the interaction of FH and FHR-3 with oxidative stress 
epitopes (manuscript in preparation).
Previous reports showed an in vitro interaction of recombi-
nant FHR-3 with heparin (Figure S4 in Supplementary Material) 
(3, 43). In order to better understand FHR-3 interaction with 
cell surfaces, we investigated whether mAb RETC-2 interferes 
with FHR-3 binding to heparin, a model for highly sulfated 
glycosaminoglycan chains. We conclude that the FHR-3–heparin 
interaction was not influenced by anti-FHR-3 mAb RETC-2 
(Figure S4 in Supplementary Material). The data indicate that 
the heparin-binding region in FHR-3 is not located in the SCR5 
domain and thus not in the C-terminus of FHR-3.
These results showed that FHR-3 competes with FH for C3b 
binding and that this can be modulated by specific mAbs to the 
SCR5 domain of FHR-3 without affecting the interaction with 
heparin.
DiscUssiOn
We here report of new, highly specific murine antibodies for a 
well-defined epitope of FHR-3, which we used for systemic as 
well as local detection and functional modulation of FHR-3. 
FHR-3 is a member of the FH protein family, which are important 
regulators of the complement system and associated with several 
diseases, such as AMD and aHUS (4). The specific detection of 
FigUre 7 | anti-Fhr-3 mab reTc-2 reduced binding of Fhr-3 to c3b. (a) FHR-3 and FH bind to C3b in a dose-dependent manner. (B) FH binding to C3b 
was reduced by FHR-3 in a dose-dependent manner. Statistic was performed using one-way ANOVA with multiple comparisons and FHR-3 (0 nM) as control 
(**p < 0.01). (c) MAb RETC-2, but not FH, reduced interaction of FHR-3 to immobilized C3b. Statistic was performed using one-way ANOVA with multiple 
comparisons and FHR-3 as control column (**p < 0.01). (D) FH binding to C3b was reduced by FHR-3. This inhibitory effect was reversed by the addition of mAb 
RETC-2. Data represent mean values +SD of three independent experiments. Statistics were performed using One-way ANOVA with multiple comparisons and FH 
as control column (****p < 0.0001) and two-tailed unpaired t-test (***p < 0.001).
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proteins depends mostly on distinct binding of antibodies to the 
target antigen. Due to the high sequence identities among the FH 
protein family, the majority of previously generated antibodies 
showed cross-reactivity with other FH-family members (Figure 
S5 in Supplementary Material) (6, 44), with the exception of mAb 
HSL1 (19). HSL1 binds to SCR4–5 of FHR-3 and was used to 
determine binding of FHR-3 to pathogens. However, a distinct 
binding epitope and functional modulation of FHR-3 using mAb 
HSL1 have not been described.
In this study, the anti-FHR-3 mAbs were generated against a 
selected peptide sequence of the SCR5 domain. The paralogous 
SCR20 in FH is known for most of disease-associated mis-
sense mutations (45–47) and binding of autoantibodies (48). 
This C-terminal domain of FH/FHR proteins also facilitates 
the binding to C3d and glycocalyx in  vivo (49) (Figure S5 in 
Supplementary Material). Therefore, it was a favorable target for 
function-modulating antibodies.
Our mAb RETC-2 specifically detected FHR-3, native and 
denatured FHR-3, but no other FHRs. SCR9 domain of FHR-4A 
showed the highest identity with the FHR-3 target domain used 
for antibody generation (93.8%). Although only two amino acids 
(aa R285 and aa R288) of the immunogen were different in the 
corresponding region of FHR-4A, mAb RETC-2 was highly spe-
cific for FHR-3 and did not interact with FHR-4A. We exclusively 
precipitated FHR-3 and no other attached FH-family member 
from human serum, which supports the hypothesis that FHR-3 
circulates as a monomer or homo-multimer in human serum, in 
contrast to FHR-1, FHR-2, and FHR-5, which form beside homo-
multimers also heterodimers and share a dimerization motif (18).
Besides a previous estimation on FHR-3 levels (5), there has 
been only one other report using an immunoassay to measure 
FHR-3 levels in healthy individuals, reporting systemic FHR-3 
levels of 0.7 μg/mL on average, and a major influence of copy 
number variation in cfhr3 on the variation of the FHR-3 levels 
within a population (6). According to the high specificity of 
mAb RETC-2, we confirmed the FHR-3 concentration in human 
serum probes derived from healthy individuals in a concentra-
tion ranged between 0.41 and 2.49  μg/mL (excluding cfhr3-
deficient donors). This concentration is lower than other soluble 
complement regulators in blood (e.g., 13–30 μg/mL properdin; 
40–100 μg/mL clusterin) (24, 50) and even 9- to 1800-fold below 
the reported systemic FH concentration (116–562 μg/mL) (51).
Previous studies on the deletion of cfhr3/cfhr1 genes revealed 
a protecting effect in AMD and IgAN but revealed a risk factor 
for aHUS and SLE (9, 10, 12, 13, 15). Serum FHR-3 concentra-
tions in patients suffering from AMD or aHUS showed a similar 
FHR-3 concentration range as healthy controls, although there 
seemed to be a trend toward higher levels in this small cohort. 
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These results should be further investigated in larger patient 
cohorts. However, in probes from patients with the autoimmune 
diseases SLE, RA, and PR threefold to fourfold increased systemic 
FHR-3 levels were detected.
Systemic lupus erythematosus is a complex disease with 
heterogeneous sub-phenotypes, which are all characterized by 
the production of autoantibodies, complement dysregulation, 
and inflammatory tissue injury (52). In previous studies, reduced 
FH levels and FH deficiency have been associated with SLE (53, 
54). This indicates that the FH-homeostasis is highly relevant 
and that FH-competitors, such as FHR-3 (5), could affect disease 
progression. While we did find significant differences in FHR-3 
levels within our SLE cohort, our results only include few patient 
samples and further studies are required to elucidate the role of 
FHR-3 in different clinical SLE phenotypes.
Additionally, we tested patients suffering from autoimmune 
diseases for FHR-3 levels, as we assumed elevated systemic FHR-3 
levels could be involved in inflammation (16). Complement acti-
vation is important in RA as immune complexes fix complement, 
resulting in the release of chemo-attractants for macrophages 
(55). It is known that FH is an important inhibitor of this comple-
ment activation in joints (56). FHR-3 has not been found to be 
involved in RA pathogenesis so far, but mouse studies recently 
revealed a higher mRNA concentration of mouse CFHR-C in 
the spleen of RA mice compared to healthy mice (57). It remains 
unclear whether increased systemic FHR-3 concentrations could 
result in local competition of FH and FHR-3 in joints and result 
in complement dysregulation.
Polymyalgia rheumatica is associated with inflammation in 
proximal joints (58) and viral stimulation of the immune system, 
including autoantibodies and classical pathway activation, has 
been proposed as a possible pathomechanism (59, 60). Almost 
30  years ago, Smith et  al. identified proteins of the FH-family 
in immune complexes of PR patients (61). According to the 
specificity of the used anti-FH antibody at that time, the detected 
proteins could correspond to FHR-2, FHR-3, FHR-4, FHR-5, or 
FH-like than to the described FH (1). An association of FHR-3 
with PR has not been described before, but increased systemic 
FHR-3 levels support the hypothesis of complement dysregula-
tion in PR.
Concluding that systemic FHR-3 levels were not exceedingly 
altered in AMD patients, we focused further on the local pres-
ence of FHR-3 to decipher the role of cfhr3/cfhr1 gene deletion in 
this disease. FHR-3 and members of the FH-family are primar-
ily known as secreted plasma proteins, which are produced in 
liver cells (40). In addition, a myeloma cell line was also tested 
positive for cfhr3 transcripts (62). Here, we describe the local 
expression of cfhr3/FHR-3 on mRNA and protein levels in the 
retina by putatively activated microglia or invading macrophages. 
Active microglia/macrophages are a common characteristic in 
retinal degenerative diseases and are associated with the release 
of inflammatory complement components (63–65). Increased 
local FHR-3 concentration in the damaged retina could influence 
the FH/FHR-3 balance. However, FHR-3 did not colocalize with 
FH in the human retina, as the FH protein was found in Müller 
and photoreceptor cell segments. So far, FH was detected at the 
choroidal site of the Bruch’s membrane and in RPE in the human 
retina (66). The previously reported FH-expressing RPE forms 
the blood-retina barrier and the Müller cells span the whole 
retina (66). Both cell types are known for complement protein 
expression, suggesting a responsibility for maintenance of the 
immune homeostasis in the eye (67–69).
The local binding and competition of FHR-3 and FH on sur-
faces is an important mechanism for the regulation of immune 
homeostasis (5, 19). We showed that 12 times more FHR-3 
than FH molecules are needed for the displacement of FH on 
immobilized C3b in vitro. Systemic physiological conditions are 
associated with a FHR-3:FH ratio of 1:33 to 1:7400 (70). This 
relationship could be altered in pathophysiological processes. 
Reduced FH concentrations in stressed RPE and the detection 
of FHR-3 produced by macrophages in the damaged retina 
suggested a local shift of the FHR-3/FH equilibrium in retinal 
degeneration (71, 72).
The interaction of mAb RETC-2 with FHR-3 partly influenced 
the competition of FHR-3 and FH for binding to C3b. As mAb 
RETC-2 binds in SCR5 of FHR-3, this suggests that SCR4 and 
SCR5 (19) of FHR-3 are involved in C3b binding (Figure S5 in 
Supplementary Material). Indeed, the relevant amino acids in 
SCR19 of FH involved in C3b binding are conserved in SCR4 and 
SCR5 of FHR-3 (22, 73) (Figure S5 in Supplementary Material). 
Our results are in agreement with previous studies, which showed 
that both C-terminal domains of FHR-3 (SCR 4–5) mediated the 
binding of FHR-3 to C3b, indicating that SCR5 is involved but not 
sufficient for C3b binding (3).
Factor H-related protein-3 interacts with cell surfaces not 
only via its C3b/C3d but also via its heparin-binding sites (3). 
MAb RETC-2 did not interfere with heparin binding to FHR-3, 
suggesting that the heparin-binding site is not located in SCR5 of 
FHR-3. These results are supported by the fact that the relevant 
amino acids for heparin binding identified in SCR20 of FH are 
not conserved in SCR5 of FHR-3 (Figure S5 in Supplementary 
Material). Instead, a high amino acid identity is present between 
SCR2 of FHR-3 and SCR7 of FH, the latter including a heparin-
binding site (1). Thus, FHR-3 probably binds with its N-terminal 
domain and not via the C-terminus to heparin (Figure S5 in 
Supplementary Material).
To date, antibodies targeting the immune system offer 
promising therapies in different autoimmune diseases (74–76). 
Based on genetic association studies, FHR-3 seems to be a Janus-
faced target: beneficial effects needed in aHUS and deleterious 
effects avoided in AMD. Inhibition of FHR-3 may therefore 
confer a therapeutic option in some autoimmune pathologies. 
Given the lack of effective therapy for the dry form of AMD 
and the reported local FHR-3 production in the damaged eye, 
FHR-3 inhibition by a humanized version of RETC-2 may be an 
effective therapeutic strategy (Figure 8). An unbalanced, local 
FHR-3/FH equilibrium could be the cause for local activation 
of microglia/macrophages in the human retina, as FH can not 
efficiently bind to the modified cell surfaces (Figure 8A). MAb 
RETC-2 interfered with FHR-3 binding to C3b fragments and 
enhanced FH binding. Our FHR-3 specific mAb may have a 
positive effect in the retina, helping to restore the local homeo-
stasis by enhanced FH binding on cell surfaces to neutralize 
stress reactions (Figure  8B). Additional investigations of the 
FigUre 8 | Putative role of Fhr-3 in retinal degeneration and the therapeutic potential of mab reTc-2. (a) FHR-3 is locally produced in the retina by 
microglia cells/invading macrophages and competes with FH for binding to C3b and modified surfaces. FHR-3 disturbs the FH-homeostasis in the retina. It 
potentially modulates complement activation following oxidative stress at the RPE/choroid and leads to progression of retinal degeneration. (B) MAb RETC-2 inhibits 
FHR-3 interaction with surfaces, lipid peroxidation products, and enhances binding of FH to C3b in the eye. This could result in a recovery of local complement 
homeostasis and a reduced progression of retinal degeneration.
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systemic role of FHR-3 in RA, SLE, and PR are necessary to 
approve a potential therapeutic effect of FHR-3 blockade in 
systemic autoimmune diseases.
cOnclUsiOn
In summary, we generated specific antibodies against FHR-3, 
which detected endogenous FHR-3 in the retina and allowed 
to determine FHR-3 serum concentrations. Enhanced serum 
levels of FHR-3 found in sera from patients with autoimmune 
diseases, such as RA, SLE, and PR, underline the important role of 
FHR-3 in homeostasis. Our study confirms that FHR-3 competes 
with FH for C3b binding via SCR5 and binds to heparin via the 
N-terminal region. As the novel RETC-2 antibody inhibits com-
petition of FHR-3 with FH and thus enhances local FH binding, 
our newly generated mAb RETC-2 may be a useful therapeutic 
target in specific autoimmune diseases.
aUThOr cOnTriBUTiOns
NS and DP developed concept and designed the study. NS, AG, 
and DP designed experiments. NS, AG, JR, SH, VE, and DP per-
formed experiments. NS, AG, BE, SH, VE, CS, and DP analyzed 
and discussed data. RP, TK, DW, BE, VE, PZ, and CS provided 
material. NS, AG, PZ, CS, and DP wrote the manuscript. RP, TK, 
and DW discussed and commented on the manuscript.
acKnOWleDgMenTs
The authors thank D. Felder, R. Föckler, E. Eckert, and 
A. Dannullis for technical assistance. They also thank the patients 
and physicians for their cooperation.
FUnDing
The authors thank the following foundations for their gener-
ous support for this project: NS was founded by the Maloch 
Foundation; AG received support from the ProRetina 
Foundation and from Deutsche Forschungsgemeinschaft (DFG) 
for the VisiScope CSU-X1 Confocal System (INST 89/386-1 
FUGG); and DP was supported by the BrightFocus Fondation 
(M2015186) and the Jackstädt Foundation.
sUPPleMenTarY MaTerial
The Supplementary Material for this article can be found 
online at http://journal.frontiersin.org/article/10.3389/fimmu. 
2016.00542/full#supplementary-material.
reFerences
1. Skerka C, Chen Q, Fremeaux-Bacchi V, Roumenina LT. Complement factor H 
related proteins (CFHRs). Mol Immunol (2013) 56(3):170–80. doi:10.1016/j.
molimm.2013.06.001 
2. Díaz-Guillén MA, Rodríguez de Córdoba S, Heine-Suñer D. A radiation hybrid 
map of complement factor H and factor H-related genes. Immunogenetics 
(1999) 49(6):549–52. doi:10.1007/s002510050534 
3. Hellwage J, Jokiranta TS, Koistinen V, Vaarala O, Meri S, Zipfel PF. Functional 
properties of complement factor H-related proteins FHR-3 and FHR-4: bind-
ing to the C3d region of C3b and differential regulation by heparin. FEBS Lett 
(1999) 462(3):345–52. doi:10.1016/S0014-5793(99)01554-9 
4. Józsi M, Zipfel PF. Factor H family proteins and human diseases. Trends 
Immunol (2008) 29(8):380–7. doi:10.1016/j.it.2008.04.008 
5. Fritsche LG, Lauer N, Hartmann A, Stippa S, Keilhauer CN, Oppermann 
M, et al. An imbalance of human complement regulatory proteins CFHR1, 
CFHR3 and factor H influences risk for age-related macular degeneration 
(AMD). Hum Mol Genet (2010) 19(23):4694–704. doi:10.1093/hmg/ddq399 
6. Pouw RB, Brouwer MC, Geissler J, van Herpen LV, Zeerleder SS, Wuillemin 
WA, et  al. Complement factor H-related protein 3 serum levels are low 
compared to factor H and mainly determined by gene copy number variation 
in CFHR3. PLoS One (2016) 11(3):e0152164. doi:10.1371/journal.pone. 
0152164 
7. Zhang P, Zhu M, Geng-Spyropoulos M, Shardell M, Gonzalez-Freire M, 
Gudnason V, et al. A novel, multiplexed targeted mass spectrometry assay for 
quantification of complement factor H (CFH) variants and CFH-related pro-
teins 1-5 in human plasma. Proteomics (2016). doi:10.1002/pmic.201600237 
8. Józsi M, Meri S. Factor H-related proteins. Methods Mol Biol (2014) 1100:225–
36. doi:10.1007/978-1-62703-724-2_18 
9. Hageman GS, Hancox LS, Taiber AJ, Gehrs KM, Anderson DH, Johnson LV, 
et al. Extended haplotypes in the complement factor H (CFH) and CFH-related 
(CFHR) family of genes protect against age-related macular degeneration: 
characterization, ethnic distribution and evolutionary implications. Ann Med 
(2006) 38(8):592–604. doi:10.1080/07853890601097030 
10. Hughes AE, Orr N, Esfandiary H, Diaz-Torres M, Goodship T, Chakravarthy 
U. A common CFH haplotype, with deletion of CFHR1 and CFHR3, is asso-
ciated with lower risk of age-related macular degeneration. Nat Genet (2006) 
38(10):1173–7. doi:10.1038/ng1890 
11. Spencer KL, Michael AH, Olson LM, Schmidt S, Scott WK, Gallins P, et al. 
Deletion of CFHR3 and CFHR1 genes in age-related macular degeneration. 
Hum Mol Genet (2008) 17(7):971–7. doi:10.1093/hmg/ddm369 
12. Gharavi AG, Kiryluk K, Choi M, Li Y, Hou P, Xie J, et  al. Genome-wide 
association study identifies susceptibility loci for IgA nephropathy. Nat Genet 
(2011) 43(4):321–7. doi:10.1038/ng.787 
13. Abarrategui-Garrido C, Martínez-Barricarte R, López-Trascasa M, de 
Córdoba SR, Sánchez-Corral P. Characterization of complement factor 
H-related (CFHR) proteins in plasma reveals novel genetic variations of 
CFHR1 associated with atypical hemolytic uremic syndrome. Blood (2009) 
114(19):4261–71. doi:10.1182/blood-2009-05-223834 
14. Zipfel PF, Edey M, Heinen S, Józsi M, Richter H, Misselwitz J, et al. Deletion 
of complement factor H-related genes CFHR1 and CFHR3 is associated with 
atypical hemolytic uremic syndrome. PLoS Genet (2007) 3(3):e41. doi:10.1371/
journal.pgen.0030041 
15. Zhao J, Wu H, Khosravi M, Cui H, Qian X, Kelly JA, et  al. Association of 
genetic variants in complement factor H and factor H-related genes with sys-
temic lupus erythematosus susceptibility. PLoS Genet (2011) 7(5):e1002079. 
doi:10.1371/journal.pgen.1002079 
16. Närkiö-Mäkelä M, Hellwage J, Tahkokallio O, Meri S. Complement-regulator 
factor H and related proteins in otitis media with effusion. Clin Immunol 
(2001) 100(1):118–26. doi:10.1006/clim.2001.5043 
17. Józsi M, Tortajada A, Uzonyi B, Goicoechea de Jorge E, Rodríguez de Córdoba 
S. Factor H-related proteins determine complement-activating surfaces. 
Trends Immunol (2015) 36(6):374–84. doi:10.1016/j.it.2015.04.008 
18. Goicoechea de Jorge E, Caesar JJ, Malik TH, Patel M, Colledge M, Johnson S, 
et al. Dimerization of complement factor h-related proteins modulates com-
plement activation in vivo. Proc Natl Acad Sci U S A (2013) 110(12):4685–90. 
doi:10.1073/pnas.1219260110 
19. Caesar JJ, Lavender H, Ward PN, Exley RM, Eaton J, Chittock E, et  al. 
Competition between antagonistic complement factors for a single protein on 
N. meningitidis rules disease susceptibility. Elife (2014) 3:1–14. doi:10.7554/
eLife.04008 
20. Russell WMS, Burch RL. The Principles of Humane Experimental Technique. 
London: Methuen, Universities Federation for Animal Welfare (UFAW) 
(1959).
21. Berra S, Clivio A. Rapid isolation of pure complement factor H from serum 
for functional studies by the use of a monoclonal antibody that discriminates 
15
Schäfer et al. Specific Antibodies for FHR-3
Frontiers in Immunology | www.frontiersin.org November 2016 | Volume 7 | Article 542
FH from all the other isoforms. Mol Immunol (2016) 72:65–73. doi:10.1016/j.
molimm.2016.03.001 
22. Buhlmann D, Eberhardt HU, Medyukhina A, Prodinger WM, Figge MT, 
Zipfel PF, et  al. FHR3 blocks C3d-mediated coactivation of human B cells. 
J Immunol (2016) 197(2):620–9. doi:10.4049/jimmunol.1600053
23. Schmidt TG, Skerra A. The Strep-tag system for one-step purification and 
high-affinity detection or capturing of proteins. Nat Protoc (2007) 2(6):1528–
35. doi:10.1038/nprot.2007.209 
24. Pauly D, Nagel BM, Reinders J, Killian T, Wulf M, Ackermann S, et al. A novel 
antibody against human properdin inhibits the alternative complement sys-
tem and specifically detects properdin from blood samples. PLoS One (2014) 
9(5):e96371. doi:10.1371/journal.pone.0096371 
25. Pauly D, Kirchner S, Stoermann B, Schreiber T, Kaulfuss S, Schade R, et al. 
Simultaneous quantification of five bacterial and plant toxins from complex 
matrices using a multiplexed fluorescent magnetic suspension assay. Analyst 
(2009) 134(10):2028–39. doi:10.1039/b911525k 
26. Laemmli UK. Cleavage of structural proteins during the assembly of the head 
of bacteriophage T4. Nature (1970) 227(5259):680–5. doi:10.1038/227680a0 
27. Thomas A, Klein MS, Stevens AP, Reinders Y, Hellerbrand C, Dettmer K, et al. 
Changes in the hepatic mitochondrial and membrane proteome in mice fed 
a non-alcoholic steatohepatitis inducing diet. J Proteomics (2013) 80:107–22. 
doi:10.1016/j.jprot.2012.12.027 
28. Wiśniewski JR, Zougman A, Nagaraj N, Mann M. Universal sample prepa-
ration method for proteome analysis. Nat Methods (2009) 6(5):359–62. 
doi:10.1038/nmeth.1322 
29. Hauck SM, Dietter J, Kramer RL, Hofmaier F, Zipplies JK, Amann B, et al. 
Deciphering membrane-associated molecular processes in target tissue of 
autoimmune uveitis by label-free quantitative mass spectrometry. Mol Cell 
Proteomics (2010) 9(10):2292–305. doi:10.1074/mcp.M110.001073 
30. Graessel A, Hauck SM, von Toerne C, Kloppmann E, Goldberg T, 
Koppensteiner H, et al. A combined omics approach to generate the surface 
atlas of human naive CD4+ T cells during early T-cell receptor activation. Mol 
Cell Proteomics (2015) 14(8):2085–102. doi:10.1074/mcp.M114.045690 
31. Dyballa N, Metzger S. Fast and sensitive colloidal coomassie G-250 staining 
for proteins in polyacrylamide gels. J Vis Exp (2009) 30:1431. doi:10.3791/1431 
32. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extract-
ing DNA from human nucleated cells. Nucleic Acids Res (1988) 16(3):1215. 
doi:10.1093/nar/16.3.1215 
33. Grosche A, Hauser A, Lepper MF, Mayo R, von Toerne C, Merl-Pham J, et al. 
The proteome of native adult Müller glial cells from murine retina. Mol Cell 
Proteomics (2016) 15(2):462–80. doi:10.1074/mcp.M115.052183 
34. Blenkinsop TA, Salero E, Stern JH, Temple S. The culture and maintenance 
of functional retinal pigment epithelial monolayers from adult human eye. 
Methods Mol Biol (2013) 945:45–65. doi:10.1007/978-1-62703-125-7_4 
35. Dunn KC, Aotaki-Keen AE, Putkey FR, Hjelmeland LM. ARPE-19, a human 
retinal pigment epithelial cell line with differentiated properties. Exp Eye Res 
(1996) 62(2):155–69. doi:10.1006/exer.1996.0020 
36. Pisitkun T, Hoffert JD, Saeed F, Knepper MA. NHLBI-AbDesigner: an online 
tool for design of peptide-directed antibodies. Am J Physiol Cell Physiol (2012) 
302(1):C154–64. doi:10.1152/ajpcell.00325.2011 
37. Retter I, Althaus HH, Münch R, Müller W. VBASE2, an integrative V gene 
database. Nucleic Acids Res (2005) 33(Database issue):D671–4. doi:10.1093/
nar/gki088 
38. Leaver-Fay A, Tyka M, Lewis SM, Lange OF, Thompson J, Jacak R, et  al. 
ROSETTA3: An object-oriented software suite for the simulation and design 
of macromolecules. Methods Enzymol (2011) 487:545–74. doi:10.1016/
B978-0-12-381270-4.00019-6 
39. Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, 
et  al. UCSF Chimera – a visualization system for exploratory research and 
analysis. J Comput Chem (2004) 25(13):1605–12. doi:10.1002/jcc.20084 
40. Zipfel PF, Skerka C. Complement factor H and Related proteins: an expanding 
family of complement-regulatory proteins? Immunol Today (1994) 15(3):121–
6. doi:10.1016/0167-5699(94)90155-4 
41. Stewart WW, Johnson A, Steward MW, Whaley K, Kerr MA. The Activation of 
C3 and C4 in human serum by immune complexes containing mouse mono-
clonal antibodies of different isotype and affinity: effects of solubilisation. 
Mol Immunol (1988) 25(12):1355–61. doi:10.1016/0161-5890(88)90051-X 
42. Seino J, Eveleigh P, Warnaar S, van Haarlem LJ, van Es LA, Daha MR. 
Activation of human complement by mouse and mouse/human chimeric 
monoclonal antibodies. Clin Exp Immunol (1993) 94(2):291–6. doi:10.111
1/j.1365-2249.1993.tb03446.x 
43. Blackmore TK, Hellwage J, Sadlon TA, Higgs N, Zipfel PF, Ward HM, et al. 
Identification of the second heparin-binding domain in human complement 
factor H. J Immunol (1998) 160(7):3342–8. 
44. Skerka C, Zipfel PF. Complement factor H related proteins in immune dis-
eases. Vaccine (2008) 26(Suppl 8):I9–14. doi:10.1016/j.molimm.2013.06.001 
45. Raychaudhuri S, Iartchouk O, Chin K, Tan PL, Tai AK, Ripke S, et al. A Rare 
penetrant mutation in CFH confers high risk of age-related macular degener-
ation. Nat Genet (2011) 43(12):1232–6. doi:10.1038/ng.976 
46. Boon CJ, Klevering BJ, Hoyng CB, Zonneveld-Vrieling MN, Nabuurs SB, 
Blokland E, et al. Basal laminar drusen caused by compound heterozygous 
variants in the CFH gene. Am J Hum Genet (2008) 82(2):516–23. doi:10.1016/j.
ajhg.2007.11.007 
47. Stephen JP, Goodship TH. Molecular modelling of the C-terminal domains 
of factor H of human complement: a correlation between haemolytic 
uraemic syndrome and a predicted heparin binding site. J Mol Biol (2002) 
316(2):217–24. doi:10.1006/jmbi.2001.5337 
48. Józsi M, Licht C, Strobel S, Zipfel SL, Richter H, Heinen S, et  al. Factor H 
autoantibodies in atypical hemolytic uremic syndrome correlate with 
CFHR1/CFHR3 deficiency. Blood (2008) 111(3):1512–4. doi:10.1182/blood- 
2007-09-109876 
49. Makou E, Herbert AP, Barlow PN. Functional anatomy of complement factor 
H. Biochemistry (2013) 52(23):3949–62. doi:10.1021/bi4003452 
50. Kujiraoka T, Hattori H, Miwa Y, Ishihara M, Ueno T, Ishii J, et  al. Serum 
apolipoprotein j in health, coronary heart disease and type 2 diabetes mellitus. 
J Atheroscler Thromb (2006) 13(6):314–22. doi:10.5551/jat.13.314 
51. Esparza-Gordillo J, Soria JM, Buil A, Almasy L, Blangero J, Fontcuberta J, et al. 
Genetic and environmental factors influencing the human factor H plasma 
levels. Immunogenetics (2004) 56(2):77–82. doi:10.1007/s00251-004-0660-7 
52. Manderson AP, Botto M, Walport MJ. The Role of Complement in the 
Development of Systemic Lupus Erythematosus. Annu Rev Immunol (2004) 
22:431–56. doi:10.1146/annurev.immunol.22.012703.104549 
53. Bao L, Haas M, Quigg RJ. complement factor H deficiency accelerates 
development of lupus nephritis. J Am Soc Nephrol (2011) 22(2):285–95. 
doi:10.1681/ASN.2010060647 
54. Chen SF, Wang FM, Li ZY, Yu F, Zhao MH, Chen M. Plasma complement 
factor H is associated with disease activity of patients with ANCA-associated 
vasculitis. Arthritis Res Ther (2015) 17:129. doi:10.1186/s13075-015-0656-8 
55. Firestein GS. Evolving concepts of rheumatoid arthritis. Nature (2003) 
423(6937):356–61. doi:10.1038/nature01661 
56. Banda NK, Mehta G, Ferreira VP, Cortes C, Pickering MC, Pangburn MK, 
et  al. Essential role of surface-bound complement factor H in controlling 
immune complex-induced arthritis. J Immunol (2013) 190(7):3560–9. 
doi:10.4049/jimmunol.1203271 
57. Mehta G, Ferreira VP, Skerka C, Zipfel PF, Banda NK. New insights into 
disease-specific absence of complement factor H related protein C in 
mouse models of spontaneous autoimmune diseases. Mol Immunol (2014) 
62(1):235–48. doi:10.1016/j.molimm.2014.06.028 
58. Salvarani C, Cantini F, Boiardi L, Hunder GG. Polymyalgia rheumatica 
and giant-cell arteritis. N Engl J Med (2002) 347(4):261–71. doi:10.1056/
NEJMra011913 
59. Uddhammar A, Boman J, Juto P, Rantapää Dahlqvist S. Antibodies against 
Chlamydia pneumoniae, cytomegalovirus, enteroviruses and respiratory 
syncytial virus in patients with polymyalgia rheumatica. Clin Exp Rheumatol 
(1997) 15(3):299–302. 
60. Knecht S, Henningsen H, Rauterberg EW. Immunohistology of temporal 
arteritis: phenotyping of infiltrating cells and deposits of complement compo-
nents. J Neurol (1991) 238(3):181–2. doi:10.1007/BF00319687 
61. Smith AJ, Kyle V, Cawston TE, Hazleman BL. Isolation and analysis of 
immune complexes from sera of patients with polymyalgia rheumatica and 
giant cell arteritis. Ann Rheum Dis (1987) 46(6):468–74. doi:10.1136/ard.46. 
6.468 
62. Uhlén M, Fagerberg L, Hallström BM, Lindskog C, Oksvold P, Mardinoglu A, 
et al. Proteomics. Tissue-based map of the human proteome. Science (2015) 
347(6220):1260419. doi:10.1126/science.1260419 
63. Karlstetter M, Scholz R, Rutar M, Wong WT, Provis JM, Langmann T. Retinal 
microglia: just bystander or target for therapy? Prog Retin Eye Res (2015) 
45:30–57. doi:10.1016/j.preteyeres.2014.11.004 
16
Schäfer et al. Specific Antibodies for FHR-3
Frontiers in Immunology | www.frontiersin.org November 2016 | Volume 7 | Article 542
64. Rutar M, Natoli R, Kozulin P, Valter K, Gatenby P, Provis JM. Analysis of 
complement expression in light-induced retinal degeneration: synthesis 
and deposition of C3 by Microglia/macrophages is associated with focal 
photoreceptor degeneration. Invest Ophthalmol Vis Sci (2011) 52(8):5347–58. 
doi:10.1167/iovs.10-7119 
65. Rutar M, Valter K, Natoli R, Provis JM. Synthesis and propagation of com-
plement C3 by microglia/monocytes in the aging retina. PLoS One (2014) 
9(4):e93343. doi:10.1371/journal.pone.0093343 
66. Clark SJ, Perveen R, Hakobyan S, Morgan BP, Sim RB, Bishop PN, et  al. 
Impaired binding of the age-related macular degeneration-associated com-
plement factor H 402H allotype to Bruch’s membrane in human retina. J Biol 
Chem (2010) 285(39):30192–202. doi:10.1074/jbc.M110.103986 
67. Sarthy VP, Park A, Dudley VJ, Johnson RJ. Complement regulatory 
protein expression by retinal Müller cells. Invest Ophthalmol Vis Sci (2012) 
53(14):ARVO Meeting Abstract 1646. 
68. Luo C, Zhao J, Madden A, Chen M, Xu H. Complement expression in retinal 
pigment epithelial cells is modulated by activated macrophages. Exp Eye Res 
(2013) 112:93–101. doi:10.1016/j.exer.2013.04.016 
69. Juel HB, Kaestel C, Folkersen L, Faber C, Heegaard NH, Borup R, et  al. 
Retinal pigment epithelial cells upregulate expression of complement factors 
after co-culture with activated T cells. Exp Eye Res (2011) 92(3):180–8. 
doi:10.1016/j.exer.2011.01.003 
70. Rodríguez de Córdoba S, Esparza-Gordillo J, Goicoechea de Jorge E, Lopez-
Trascasa M, Sánchez-Corral P. The human complement factor H: functional 
roles, genetic variations and disease associations. Mol Immunol (2004) 
41(4):355–67. doi:10.1016/j.molimm.2004.02.005 
71. Marazita MC, Dugour A, Marquioni-Ramella MD, Figueroa JM, Suburo AM. 
Oxidative stress-induced premature senescence dysregulates VEGF and CFH 
Expression in retinal pigment epithelial cells: implications for age-related 
macular degeneration. Redox Biol (2016) 7(April):78–87. doi:10.1016/j.
redox.2015.11.011 
72. Bhutto IA, Baba T, Merges C, Juriasinghani V, McLeod DS, Lutty GA. 
C-reactive protein and complement factor H in aged human eyes and eyes with 
age-related macular degeneration. Br J Ophthalmol (2011) 95(9):1323–30. 
doi:10.1136/bjo.2010.199216 
73. Jokiranta TS, Hellwage J, Koistinen V, Zipfel PF, Meri S. Each of the three 
binding sites on complement factor H interacts with a distinct site on C3b. 
J Biol Chem (2000) 275(36):27657–62. doi:10.1074/jbc.M002903200 
74. Volz C, Pauly D. Antibody therapies in age-related macular degeneration 
and challenges. Eur J Pharm Biopharm (2015) 95:158–72. doi:10.1016/j.
ejpb.2015.02.020 
75. Zuber J, Fakhouri F, Roumenina LT, Loirat C, Frémeaux-Bacchi V; French 
Study Group for aHUS/C3G. Use of eculizumab for atypical haemolytic 
uraemic syndrome and C3 glomerulopathies. Nat Rev Nephrol (2012) 
8(11):643–57. doi:10.1038/nrneph.2012.214 
76. Inui K, Koike T. Combination therapy with biologic agents in rheumatic 
diseases: current and future prospects. Ther Adv Musculoskelet Dis (2016) 
8(5):192–202. doi:10.1177/1759720X16665330 
Conflict of Interest Statement: NS, AG, JR, SH, RP, TK, DW, BE, VE, CS, and 
DP declare that the research was conducted in the absence of any commercial or 
financial relationships that could be construed as a potential conflict of interest. PZ 
received speaker honorarium from Alexion Pharmaceuticals.
Copyright © 2016 Schäfer, Grosche, Reinders, Hauck, Pouw, Kuijpers, Wouters, 
Ehrenstein, Enzmann, Zipfel, Skerka and Pauly. This is an open-access article 
distributed under the terms of the Creative Commons Attribution License (CC BY). 
The use, distribution or reproduction in other forums is permitted, provided the 
original author(s) or licensor are credited and that the original publication in this 
journal is cited, in accordance with accepted academic practice. No use, distribution 
or reproduction is permitted which does not comply with these terms.
